DHS 157.62(3)(c)2.
2. A combination of direct measurements of radioactivity and mathematical calculations.
DHS 157.62(3)(c)3.
3. A combination of volumetric measurements and mathematical calculations, based on the measurement made by a manufacturer or preparer licensed under s.
DHS 157.13 (4) (i), a PET radioactive drug producer licensed under s.
DHS 157.13 (1) (j), or equivalent NRC or other agreement state requirements.
DHS 157.62(3)(d)
(d) Unless otherwise directed by the authorized user, a licensee may not use a dosage if the dosage differs from the prescribed dosage by more than 20% or if the dosage does not fall within the prescribed dosage range.
DHS 157.62(4)
(4)
Authorization for calibration, transmission and reference sources. DHS 157.62(4)(a)
(a) Any person authorized by s.
DHS 157.13 (5) for medical use of radioactive material may receive, possess and use any of the following radioactive material for check, calibration, transmission and reference use:
DHS 157.62(4)(a)1.
1. A sealed source that does not exceed 1.11 GBq (30 mCi) that is manufactured and distributed by a person licensed under s.
DHS 157.13 (4) (j) or equivalent NRC or agreement state regulations or redistributed by a person authorized to redistribute sealed sources, provided that the redistributed sealed sources are in the original packaging and shielding and are accompanied by the manufacturer's approved instructions.
DHS 157.62(4)(a)2.
2. Any radioactive material with a half-life not longer than 120 days in individual amounts not to exceed 0.555 GBq (15 mCi).
DHS 157.62(4)(a)3.
3. Any radioactive material with a half-life longer than 120 days in individual amounts not to exceed the smaller of 7.4 MBq (200 microcuries) or 1000 times the quantities in ch.
DHS 157 Appendix F.
DHS 157.62(4)(b)
(b) Radioactive material in sealed sources authorized by this subsection shall not be used in either of the following:
DHS 157.62(4)(b)2.
2. Bundled or aggregated to create activity greater than the maximum activity of any single sealed source authorization under this section.
DHS 157.62(4)(c)
(c) A licensee using calibration, transmission, and reference sources in accordance with the requirements in this subsection need not list these sources on a specific medical use license.
DHS 157.62(5)
(5)
Requirements for possession of sealed sources and brachytherapy sources. DHS 157.62(5)(a)
(a) A licensee in possession of any sealed source or brachytherapy source shall follow the radiation safety and handling instructions supplied by the manufacturer.
DHS 157.62(5)(b)
(b) A licensee in possession of a sealed source shall do both the following:
DHS 157.62(5)(b)1.
1. Test the source for leakage before its first use unless the licensee has a certificate from the supplier indicating that the source was tested within 6 months before transfer to the licensee.
DHS 157.62(5)(b)2.
2. Test the source for leakage at intervals not to exceed 6 months or at other intervals approved by the department, NRC or another agreement state in the sealed source and device registry.
DHS 157.62(5)(b)3.
3. Test the source for leakage at any time there is reason to suspect that the sealed source might have been damaged or might be leaking.
DHS 157.62(5)(c)
(c) To satisfy the leak test requirements of this section, a licensee shall measure the sample so that the leakage test may detect the presence of 185 Bq (0.005
µCi) of radioactive material on the sample.
DHS 157.62(5)(e)
(e) If the leakage test reveals the presence of 185 Bq (0.005
µCi) or more of removable contamination, a licensee shall do both the following:
DHS 157.62(5)(e)1.
1. Immediately withdraw the sealed source from use and store, dispose or cause it to be repaired under the requirements in subchs.
II and
III.
DHS 157.62(5)(f)
(f) A licensee need not perform a leakage test on any of the following sources:
DHS 157.62(5)(f)1.
1. A source containing only radioactive material with a half-life of less than 30 days.
DHS 157.62(5)(f)3.
3. A source containing 3.7 MBq (100
µCi) or less of beta or gamma-emitting material or 0.37 MBq (10
µCi) or less of alpha-emitting material.
DHS 157.62(5)(f)4.
4. A source stored and not being used. A licensee shall, however, test each source for leakage before any use or transfer unless it has been leakage-tested within 6 months before the date of use or transfer.
DHS 157.62(5)(g)
(g) A licensee in possession of sealed sources or brachytherapy sources, except for gamma stereotactic radiosurgery sources, shall conduct a semi-annual physical inventory of all such sources in its possession. A licensee shall retain each inventory record under s.
DHS 157.71 (9).
DHS 157.62(6)
(6)
Labelling of vials and syringes. Each syringe and vial that contains a radioactive drug containing radioactive material shall be labeled to identify the radioactive drug.
Each syringe shield and vial shield shall also be labeled unless the label on the syringe or vial is visible when shielded.
DHS 157.62(7)(a)
(a) Except as provided in par.
(b), a licensee shall survey with a radiation detection survey instrument at the end of each day of use all areas where radioactive drugs containing radioactive material requiring a written directive were prepared for use or administered.
DHS 157.62(7)(b)
(b) A licensee need not perform the surveys required under par.
(a) in an area where patients or human research subjects are confined when the patients or human research subjects cannot be released under sub.
(8).
DHS 157.62(8)
(8)
Release of individuals containing radioactive drugs or implants containing radioactive material. DHS 157.62(8)(a)
(a) A licensee may authorize the release from its control of any person who has been administered radioactive drugs or implants containing radioactive material if the total effective dose equivalent to any other person from exposure to the released individual is not likely to exceed 5 mSv (0.5 rem).
DHS 157.62 Note
Note: WISREG 1556, Vol. 9, Guidance for Medical Use of Radioactive Material describes methods for calculating doses to other individuals and contains tables of activities not likely to cause doses exceeding 5 mSv (0.5 Rem). It is available from the following website:
http://dhs.wisconsin.gov/radiation/radioactivematerials/index.htm.
DHS 157.62(8)(b)
(b) A licensee shall provide the released person or the person's parent or guardian with instructions, including written instructions, on actions recommended to maintain doses to other persons as low as is reasonably achievable if the total effective dose equivalent to any other person is likely to exceed one mSv (0.1 rem). If the total effective dose equivalent to a breast-feeding infant or child could exceed one mSv (0.1 rem) assuming there were no interruption of breast-feeding, the instructions shall also include all the following:
DHS 157.62(8)(b)2.
2. Any information on the potential consequences of failure to follow the guidance.
DHS 157.62(9)(a)
(a) A licensee providing mobile medical service shall do all of the following:
DHS 157.62(9)(a)1.
1. Obtain a letter signed by the management of each client for which services are rendered by the licensee that permits the use of radioactive material at the client's address and clearly delineates the authority and responsibility of the licensee and the client.
DHS 157.62(9)(a)2.
2. Check instruments used to measure the activity of unsealed radioactive materials for proper function before medical use at each client's address or on each day of use, whichever is more frequent. The check for proper function shall include a test to verify accurate calibration using a known radioactive source.
DHS 157.62(9)(a)3.
3. Check survey instruments for proper operation with a dedicated check source before use at each client's address.
DHS 157.62(9)(a)4.
4. Before leaving a client's address, survey all areas of use to ensure compliance with the requirements in subch.
III.
DHS 157.62(9)(b)
(b) A mobile medical service may not have radioactive material delivered from the manufacturer or the distributor to the client unless the client has a license allowing possession of the radioactive material. Radioactive material delivered to the client shall be received and handled in conformance with the client's license.
DHS 157.62(10)(a)(a) A licensee may hold radioactive material with a physical half-life of less than 120 days for decay-in-storage before disposal without regard to its radioactivity if the licensee does both the following:
DHS 157.62(10)(a)1.
1. Monitors radioactive material at the surface before disposal and determines that its radioactivity cannot be distinguished from the background radiation level with an appropriate radiation detection survey meter set on its most sensitive scale and with no interposed shielding.
DHS 157.62(10)(a)2.
2. Removes or obliterates all radiation labels except for material that will be handled as biomedical waste after it has been released.
DHS 157.62 History
History: CR 01-108: cr.
Register July 2002 No. 559, eff. — see Note at the start of the chapter; corrections in (9) (c) and (10) (b) made under s. 13.93 (2m) (b) 7., Stats.,
Register July 2002 No. 559;
CR 06-021: am. (2) (a), (3) (b) 2. a., (4) (intro.) and (8) (d)
Register October 2006 No. 610, eff. 11-1-06;
CR 09-062: am. (1) (b) and (3) (c) 3., cr. (3) (b) 2. c.
Register April 2010 No. 652, eff. 5-1-10; correction in (4) (b) made under s. 35.17, Stats.,
Register January 2018 No. 745;
CR 22-015: r. and recr. (4), cr. (5) (b) 3. Register June 2023 No. 810, eff. 7-1-23. DHS 157.63
DHS 157.63 Unsealed radioactive material — written directive not required. DHS 157.63(1)(1)
Use of unsealed radioactive material for uptake, dilution and excretion studies for which a written directive is not required. A licensee may use for uptake, dilution or excretion studies any unsealed radioactive material, except in quantities that require a written directive under s.
DHS 157.61 (4), prepared for medical use that meets any of the following requirements:
DHS 157.63 Note
Note: Uptake, dilution and excretion studies determine the amount of radioactive material absorbed by a patient and the patient's ability to excrete the remainder of the radioactive material.
DHS 157.63(1)(b)
(b) Excluding production of PET radionuclides, is prepared by any of the following:
DHS 157.63(1)(c)
(c) Is obtained from an NRC or agreement state licensee for use in research under a radioactive drug research committee-approved protocol or an investigational new drug protocol accepted by the FDA.
DHS 157.63(1)(d)
(d) Is prepared by the licensee for use in research under a radioactive drug research committee-approved application or an investigational new drug protocol accepted by the FDA.
DHS 157.63(2)
(2)
Use of unsealed radioactive material for imaging and localization studies for which a written directive is not required. A licensee may use for imaging and localization studies any unsealed radioactive material, except in quantities that require a written directive under s.
DHS 157.61 (4), prepared for medical use that meets any of the following requirements:
DHS 157.63(2)(b)
(b) Is prepared by, excluding production of PET radionuclides, any of the following:
DHS 157.63(2)(c)
(c) Is obtained from a NRC or agreement state licensee for use in research under a radioactive drug research committee-approved protocol or an investigational new drug protocol accepted by the FDA.
DHS 157.63(2)(d)
(d) Is prepared by the licensee for use in research under a radioactive drug research committee-approved application or an investigational new drug protocol accepted by the FDA.
DHS 157.63(3)(a)
(a) A licensee may not administer to humans a radioactive drug containing more than the following:
DHS 157.63(3)(a)1.
1. 0.15 kilobecquerel of molybdenum-99 per megabecquerel of technetium-99m (0.15 microcurie of molybdenum-99 per 1 millicurie of technetium 99m).
DHS 157.63(3)(a)2.
2. 0.02 kilobecquerel of strontium-82 per megabecquerel of rubidium-82 chloride injection (0.02 microcurie of strontium-82 per 1 millicurie of rubidium-82 chloride injection).
DHS 157.63(3)(a)3.
3. 0.2 kilobecquerel of strontium-85 per megabecquerel of rubidium-82 chloride injection (0.2 microcurie of strontium-85 per 1 millicurie of rubidium-82 chloride injection).
